Arvac

Equine Arteritis Vaccine

Modified Live Virus

Composition

ARVAC is a desiccated preparation containing viable modified Equine Arteritis virus propagated on an equine cell line culture system.

This vaccine has been tested and shown to be satisfactory for marketing in accordance with procedures required by the U.S. Department of Agriculture.

Disease Information

Equine Arteritis Virus (EAV) is known to infect only equines. The severity of the disease is variable ranging from highly acute to subclinical in nature. The acute disease is characterized clinically by fever, leukopenia, depression, nasal discharge, lacrimation, conjunctivitis, photophobia, edema of the face, limbs, transient maculopapular skin rash and produces abortion in pregnant mares. The most consistent clinical signs have been hyperthermia, leukopenia and edema of the eye. There may be colic, diarrhea and severe loss of weight with dehydration.

Arvac Indications And Dosage

This product has been shown to be effective for the vaccination of healthy adult horses against disease caused by equine arteritis virus. Duration of immunity has not been established. For more information regarding efficacy and safety data, go to productdata.aphis.usda.gov.

Aseptically rehydrate the freeze-dried vaccine with the sterile diluent provided, shake well, and administer a single 1-mL dose intramuscularly.

Vaccinate males and young animals between 6 and 12 months of age. Stallions should be vaccinated not less than 3 weeks prior to breeding. Vaccinate mares as maidens or when open, as safety has not been demonstrated in pregnant mares. Maiden and barren mares may be vaccinated anytime but should be vaccinated not less than 3 weeks prior to breeding. For advice on revaccination frequency, contact your veterinarian or the manufacturer.

Arvac Caution

Store at 2°-8°C. Prolonged exposure to higher temperatures and/or direct sunlight may adversely affect potency. Do not freeze.

Use entire contents within 60 minutes after hydration.

Inactivate unused contents before disposal.

Do not vaccinate within 21 days before slaughter.

Contains neomycin, polymyxin B, and amphotericin B as preservatives.

Do not mix with other products, except as specified above.

In case of human exposure, contact a physician.

PLEASE TAKE NOTICE

The indications for vaccination against EVA have been to protect stallions against infection and subsequent development of the carrier state and immunize seronegative mares before being bred with EAV-infective semen in order to curtail outbreaks. For more information on revaccination in the face of stress or an exposure, contact your veterinarian or the manufacturer.

The vaccinal virus has been modified to the extent that it may be irregularly infective when given by natural portals of entry. Vaccination of foals less than 6 weeks of age is not recommended except in emergency situations when threatened by natural exposure. Management strategies based on vaccination of pregnant animals with modified live vaccines should be discussed with a veterinarian. Horse owners are to be advised of the possibility of fetal infection before vaccination of pregnant mares.

It is not possible to differentiate a vaccine-induced antibody response from one due to natural infection. Prior to initiating a vaccination program, it is advisable to establish a record of a horse’s negative EVA status by testing serum via EVA virus neutralization at a USDA-approved laboratory for all first-time vaccinates. Testing should be performed immediately prior to vaccination.

Many countries have regulations governing the import of horses serologically positive to EVA. Prior to vaccination, it is advisable to consult one of the USDA APHIS VS EXPORT SERVICE CENTERS to determine specific import requirements. Countries that accept horses serologically positive to EVA typically require a certified vaccination history including confirmation of pre-vaccination negative serological status and annual revaccination at 12-month intervals.

In planning a vaccination program against EVA, it is important to consult with state and/or federal animal health officials to ensure that any such program is in compliance with the state’s control program for EVA, if one exists. Distribution shall be limited to those States where authorized by proper State officials and under such additional conditions as these authorities may require.

ADDITIONAL ONLINE INFORMATION

American Association of Equine Practitioners (AAEP): Equine Viral Arteritis vaccination guidelines

Animal and Plant Health Inspection Service, U.S. Department of Agriculture: Factsheet: Equine Viral Arteritis

Distribution shall be limited to those States where authorized by proper State officials and under such additional conditions as these authorities may require.

For Veterinary Use Only

Technical inquiries should be directed to Zoetis Inc. Veterinary Services, (888) 963-8471.

VLN 190/PCN 1531.20

Zoetis Inc., Kalamazoo, MI 49007, USA

40039240

CPN: 3690275.4